Update for Oct. 4, 2021:
Did you miss the live stream of the PFDD meeting on food allergy? You can watch the recording.
You can still share your experiences living with and managing food allergy. Send in your comments by Oct. 9, 2021.
We will include your comments in the upcoming food allergy “Voice of the Patient Report.” We will send this report to FDA representatives. By sharing your story, you can help influence the future of treatments for food allergies.
The Asthma and Allergy Foundation of America (AAFA), as a founding member of the Food Allergy Collaborative, held a patient-focused drug development (PFDD) meeting for food allergy on Sept. 9, 2021.
The purpose of PFDD meetings is to help ensure that patients’ experiences, perspectives, needs, and priorities are represented in the drug development process. As new treatment options are developed for food allergy, it is important that the FDA and other key stakeholders – including medical product developers, health care providers, and federal partners – hear directly from patients, their families, caregivers, and patient advocates.
This meeting was an externally-led PFDD meeting, hosted by the Food Allergy Collaborative, not the FDA. The founding members of the Food Allergy Collaborative are:
- Allergy & Asthma Network (AAN)
- Asthma and Allergy Foundation of America (AAFA)*
- Elijah-Alavi Foundation
- Food Allergy & Anaphylaxis Connection Team (FAACT)
- Food Allergy Fund
- Food Allergy Research and Education (FARE)
- Food Equality Initiative
Learn Why Patient-Focused Drug Development Meetings Are Important
Want to learn more about why PFDD meetings are important for the future of food allergy management and treatment? Watch the recording from our recent webinar called “Food Allergy Voice of the Patient Process.”
The webinar below is your opportunity to learn more about PFDD meetings and why they are important for the food allergy community. You will learn about the project and how you can get involved.